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New partnership stands to save millions 
of mothers and children
Two of several health inno-
vations that could save the 
lives of millions of mothers 
and babies will probably 
reach the South African 
(SA) market first – years ahead of schedule 
– because of a new partnership between the 
government, the South African Medical 
Research Council (MRC) and a leading 
international NGO.
With postpartum haemorrhage the lead-
ing cause of maternal mortality worldwide, 
the first innovation is a breathtakingly simple 
improvement on the first-line preventive 
medicine currently in use – the heat-sensitive 
injectable oxytocin. The intended product, 
a pill formulation, solves the longstanding 
dilemma of storage and supply chain 
management of liquid oxytocin in rural and/
or under-resourced areas, where most of the 
deaths occur. Not only will the prospective 
heat-stable ‘under-the-tongue’ fast-dissolving 
oxytocin pill be easier to store and manage, 
but less-skilled healthcare workers will be able 
to administer it, enabling quicker, better and 
more accessible prevention and treatment 
all round. The fixed-dose presentation has 
proved highly successful in animal studies 
and can withstand temperatures of up to 
40oC for several months, making it ideal for 
tropical and subtropical climates, where most 
maternal deaths occur.
Cutting R&D-to-market 
time by two-thirds
Developed by PATH, international non-profit 
leader in global health innovation, this is but 
one example of how products and devices can 
benefit from a health innovation accelerator 
initiative and partnership. PATH has now 
teamed up with SA’s Department of Science 
and Technology and the MRC to apply the 
same booster principles locally, prioritising key 
gaps in maternal and infant health. PATH 
are specialists in accelerating innovation for 
vaccines, drugs, diagnostics, devices, systems 
and services, typically applying their knowledge 
and channelling funding to cut research and 
development-to-market time by up to two-
thirds. On average, it takes up to 15 years 
for a product to reach the market. SA’s track 
record and successes in these fields make it 
the ideal partner, enabling PATH to accelerate 
clinical trials and regulatory approval and 
bring products to scale far sooner than would 
otherwise have been the case. 
One local example of why PATH has quietly 
invested over R3.5 million in MRC activities 
over the past 3 years is a Stellenbosch University 
medical school-developed dev ice called 
the ‘Umbiflow’, a mobile and highly versatile 
Doppler waveform analyser measuring placental 
insufficiency in small-for-gestational-age babies 
in the third trimester. In MRC President Prof. 
Glenda Gray’s estimation, this would be the 
second of the two accelerated innovations to 
hit the local market first. Priceless in enabling 
early identification of potential birth problems 
and almost certain to generate major savings 
by avoiding unnecessary upward referrals, the 
Umbiflow was developed by the MRC and the 
Council for Scientific and Industrial Research 
(CSIR) under a grant from the former Innovation 
Fund, a Department of Science and Technology-
funded vehicle established to support local 
innovation. The machine detects blood flow 
within the umbilical cord, ascertaining placental 
function via a hand-held probe (similar to a 
sonar scan), but is connected with a USB cable to 
any Windows-based computer. By installing the 
necessary software, an integrated 3G card enables 
a mobile internet connection and automatic 
upload of exam results to a central server for 
remote expert support and electronic health 
record management. PATH will help accelerate 
the project even further, supporting continuing 
evaluation and subsequent implementation in 
antenatal facilities country-wide, with potential 
adoption by health systems across the African 
continent.
Leading by example with 
life-changing products 
and meds
Speaking at the launch of the MRC-PATH 
Global Health Innovation Accelerator 
(GHIA), Dr Ayo Ajayi, PATH’s vice-president 
of international development, lauded SA’s 
culture of innovative research dating back to 
Chris Barnard’s first human-to-human heart 
transplant in 1967. He summed up PATH’s 
mission as ‘to get the best ideas and solutions 
and to translate and implement them where 
they can do the most good’, taking innovations 
to scale to tackle the greatest health needs. 
He said that SA’s deep expertise in vaccine 
development, drugs and devices made it the 
ideal partner to ‘add the multiplier effect’ by 
doing what PATH did best: getting involved 
in the middle stages of development, or the 
value chain. Globally PATH had reached 290 
million people through various technological 
innovations so far, one of the most impressive 
being a meningitis A vaccine to which 153 
million people across the 26 African countries 
where the disease is prevalent have had 
access over the past 4 years – its Indian 
manufacturer willing and able to churn it out 
for under 50 cents a dose. With the help of 
the World Health Organization, the vaccine 
was produced at one-tenth of the ‘normal’ 
research and development costs-to-market. 
Another notable PATH success story is the 
vaccine vial monitor, a tiny sticker put on vials 
of vaccine that changes colour when exposed 
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to heat. Healthcare workers can tell at a glance 
whether heat-sensitive drugs are damaged. 
Ajayi said that more than five million stickers 
had been used worldwide so far.
Why we need life-saving 
innovation for mothers 
and babies
Speaking at the 8 August launch of the GHIA, 
Dr Nonhlanhla Dlamini, Chief Director of 
Child, Adolescent and School Health in the 
National Department of Health, illustrated just 
how badly needed effective new solutions are. 
She said that one-third of the country’s under-
5 child mortality figures were due to just 
three newborn causes: prematurity, infection 
and birth asphyxia. ‘If we can get a handle on 
these, we can overcome newborn deaths,’ she 
asserted. Broader under-5 mortality causes 
included diarrhoea, pneumonia, AIDS-
related illnesses and tuberculosis. She said 
that 65% of children who died in SA were 
malnourished, prompting the current African 
Union-funded infant and young child feeding 
policy. Recent innovations that were proving 
a huge success included the locally developed 
human papillomavirus vaccine, currently 
being administered with parental permission 
to all girls in grade 4 at state schools (3 000 
SA women a year die of this cancer). The 
subdermal contraceptive implant was also 
being offered to girls who could legally opt to 
use it (from the age of 12). Of the one million 
women who fell pregnant in SA annually, 
8% were girls below the age of 18. These 
minors were giving birth to 80 000 unplanned 
babies annually, contributing to 36% of all 
maternal deaths, with their youth contributing 
to fatalities. Dlamini said that other new 
vaccines added to the preventive arsenal (in 
2009) were the rotavirus and pneumococcal 
vaccines. Their efficacy was vividly illustrated 
by the MRC’s own rapid mortality survey this 
year, which showed a drop in the under-5 
mortality rate from 56/1 000 children in 2009 
to 41/1 000 in 2012.
Local products making 
global impact
Dr Phil Mjwara, Director-General in the Depart-
ment of Science and Technology, said among the 
projects currently being piloted was an early-
warning computer system for infectious diseases 
in Limpopo Province, including meningitis and 
water-borne diseases. Several companies had 
been born out of research efforts, including 
Kapa Biosystems, which had developed rea-
gents and kits for a number of DNA analysis 
applications such as real-time polymerase chain 
reaction (PCR) and high-fidelity PCR and 
molecular diagnostics. This company, which 
now exports its products, had expanded its 
local manufacturing base and research and 
development operations. Another major success 
story was Altis Biologics, which is on the verge 
of registering its regenerative biological implants 
as a fast and safe alternative to surgery for bone 
trauma patients. The injectable product was one 
of the most commercially viable and promising 
innovations he’d seen, winning the 2014 
Innovation Prize Africa Award. Mjwara said 
that his department’s collaboration with PATH 
and the MRC would ‘benefit us tremendously 
as we seek to address the challenges of know-
ledge translation for South Africans’. The initial 
focus of the partnership would save ‘millions’ of 
vulnerable women and children in the country, 
he added.
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